Other substances

VH3 B01

A multivalent anti-SARS-CoV-2 spike protein antibody/nanobody construct.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

VH3 B01 is a trivalent construct containing three identical (B01) VH domains derived from Trastuzumab. VH B01 has been modified and selected using masked phage selection for its affinity to the SARS-CoV-2 spike protein (Bracken et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Spike protein In vitro Antibody 		HEK-ACE2 cells; Vero E6 cells; SARS-CoV-2 virus clinical isolate 2019-nCoV/USA-WA1/2020 12.15

The trivalent construct displays 1,400-fold increase in pseudotyped SARS-CoV-2 neutralization (IC50 0.156 nM) compared to its monovalent counterpart. It blocks the authentic SARS-CoV-2 viral entry (3.98 nM) in vitro, as well.

 Oct/20/2020
Export (.csv)